Kidney Stones & Ozempic: Clinical Evidence & Safety

Last reviewed: May 30, 2026

Last updated: May 30, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Kidney stones are not formally reported as a side effect of Ozempic in FDA-approved clinical trial data. However, certain physiological changes associated with GLP-1 receptor agonists—including reduced fluid intake, weight loss, and metabolic shifts—may theoretically increase kidney stone risk in predisposed individuals. Understanding whether you fall into a higher-risk category requires medical evaluation.

Patients considering GLP-1 therapy should approach safety with precision, not assumptions. PlexusDx emphasizes personalized risk assessment: genetic factors, baseline kidney function, hydration patterns, and family history all inform whether GLP-1 treatment is appropriate and how to monitor for complications. This data-driven approach helps you and your provider make informed decisions.

What Clinical Trials Actually Show About GLP-1 and Kidney Health

Phase 3 clinical trials for semaglutide and tirzepatide did not identify kidney stones as a primary adverse event. Rare kidney-related complications reported include acute kidney injury in patients with severe dehydration or pre-existing renal disease. The connection to stones specifically remains primarily theoretical and linked to indirect risk factors rather than the drug itself.

Key trials monitored renal function via creatinine and eGFR. Most patients showed stable or improved kidney markers. However, individual variation exists: patients with low baseline eGFR, chronic kidney disease, or conditions predisposing to stone formation warrant closer scrutiny and provider oversight before initiating GLP-1 therapy.

Dehydration and Metabolic Changes: The Indirect Risk Pathway

GLP-1 agonists slow gastric emptying and reduce appetite, which can lead to decreased overall fluid and nutrient intake if patients do not deliberately maintain hydration. Dehydration concentrates urine, elevating the risk of crystal formation—a known mechanism for kidney stone development. This is an indirect effect, not a direct pharmacological action of the drug.

Risk Factor	Mechanism	How It May Relate to Kidney Stones	Mitigation Strategy
Reduced fluid intake	Appetite suppression from GLP-1 action	Concentrated urine increases stone formation risk	Intentional daily hydration monitoring (aim for pale urine color)
Rapid weight loss	Increased fat and protein mobilization	Higher uric acid and calcium excretion	Gradual dose escalation; provider-recommended electrolyte checks
Low-carb diet adoption	Common dietary choice with GLP-1 use	May increase purine and uric acid levels	Balanced macronutrient intake; discuss diet with provider or dietitian
Pre-existing renal disease	Baseline kidney dysfunction	Already elevated stone risk; GLP-1 may worsen concentration	Baseline kidney function testing; possible GLP-1 avoidance

Who Is at Higher Risk and Needs Additional Monitoring

Patients with a personal or family history of kidney stones, chronic kidney disease (eGFR below 60), recurrent urinary tract infections, or gout carry elevated baseline risk. These individuals should undergo renal function testing and a detailed stone history before starting any GLP-1 agent. Your provider may recommend adjusted dosing, enhanced hydration protocols, or alternative therapies.

Certain genetic variants associated with stone formation or uric acid metabolism can influence individual susceptibility. Understanding your metabolic predisposition—through genetic testing and baseline bloodwork—allows your provider to establish preventive measures: targeted hydration schedules, dietary adjustments, or more frequent kidney function monitoring during treatment.

Safety Strategies and Provider Decision-Making Framework

Before initiating GLP-1 therapy, a comprehensive safety evaluation should include baseline serum creatinine, eGFR, uric acid, and calcium levels. A detailed personal and family history of kidney stones, gout, or renal disease is essential. Providers may order imaging if stone history is significant. This baseline data informs whether GLP-1 is appropriate and guides monitoring frequency.

During treatment, maintain consistent hydration (most providers recommend 8–10 cups daily), monitor urine color, report any flank pain or urinary symptoms immediately, and attend scheduled kidney function checks. If you develop signs of kidney stones—severe back or side pain, painful urination, or blood in urine—seek emergency care. Open communication with your provider about dietary changes, supplement use, and hydration habits is crucial for safe GLP-1 use.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test can help provide context about your genetic predispositions in GLP-1 receptor and metabolic pathways. Key variants related to weight regulation and metabolic response may indirectly inform your provider about expected physiological changes and whether enhanced kidney monitoring is warranted. This information should be interpreted with a qualified healthcare provider alongside clinical evaluation.

The genetic test reveals predispositions in peptide-related pathways—including MC4R variants—that influence how your body responds to GLP-1 therapy and metabolic stress. However, the test does not predict exact medication response or guarantee kidney stone risk. It provides one layer of personalization that, combined with blood work and clinical history, supports a more comprehensive safety assessment.

Discussing your genetic insights with your provider can support a more informed conversation about whether GLP-1 is right for you, what hydration and monitoring protocols make sense, and whether additional baseline testing is necessary. This precision-wellness approach reduces guesswork and helps you start treatment confidently.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection is $289/mo month-to-month, or from $249/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

Were kidney stones flagged as a side effect in the trials behind Ozempic?

No. The article states kidney stones are not formally reported as a side effect of Ozempic in FDA-approved clinical trial data, and that Phase 3 trials of semaglutide and tirzepatide did not identify them as a primary adverse event. The rare kidney complications those trials did record were acute kidney injury in people with severe dehydration or pre-existing renal disease. The post treats the stone connection as theoretical and indirect.

How could appetite suppression end up raising stone risk?

Indirectly, through fluid intake. The article explains that GLP-1 agonists slow gastric emptying and reduce appetite, so overall fluid and nutrient intake can drop if hydration is not deliberately maintained. Dehydration concentrates urine, and concentrated urine makes crystal formation more likely. The post is explicit that this is a downstream effect of eating and drinking less, not a direct pharmacological action of the drug.

Why does the article list rapid weight loss as its own risk factor?

Because of what the body mobilizes when weight comes off fast. The post's risk-factor table pairs rapid weight loss with increased fat and protein mobilization, which it links to higher uric acid and calcium excretion, both relevant to stone formation. The same table lists gradual dose escalation and provider-recommended electrolyte checks as the mitigation, and flags low-carb eating separately through purine and uric acid load.

Which baseline labs does this article want in hand when there is a stone history?

The article lists baseline serum creatinine, eGFR, uric acid, and calcium levels, alongside a detailed personal and family history of kidney stones, gout, or renal disease. It adds that providers may order imaging when the stone history is significant. That baseline data is what informs whether GLP-1 therapy is appropriate at all, and how often kidney function should be rechecked during treatment.

Which urinary symptoms does the post treat as an emergency rather than a routine call?

The post says severe back or side pain, painful urination, or blood in urine should prompt emergency care rather than a routine message to your provider. Separately, it asks patients to report any flank pain or urinary symptoms promptly and to keep scheduled kidney function checks. Groups it flags for closer watching include people with prior stones, chronic kidney disease, recurrent urinary tract infections, or gout.

Related Reading

• Ozempic Side Effects
• How Do Genes Affect Oxalate Sensitivity And Kidney Stones
• Lifemd Ozempic
• Eden Ozempic

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.